Social and Personal Costs of Arthritis and Rheumatic Diseases
Hide / Show Abstract

Social and Personal Costs of Arthritis and Rheumatic Diseases

An Exploratory Survey

Musculoskeletal conditions are the most common cause of severe pain, physical disability and temporary absence from work amongst the advanced nations. They are estimated to consume up to 3% of gross domestic product in Western countries in an average year. Arthritis and rheumatic diseases are a large part of these conditions and they are thus a major burden on society's health and social care services. They are even more pronounced as sources of personal burdens and reduced participation in employment and society in general. Women are on the whole significantly more affected by rheumatic diseases than men. The present pilot report surveys these differing cost environments in Denmark, Finland, Iceland, Norway and Sweden. The work was carried out for the Nordic Rheuma Council (NRR). The author, Stefán Ólafsson, is a professor of sociology at the University of Iceland.

Click to Access: 
    http://oecd.metastore.ingenta.com/content/3808801e.pdf
  • PDF
  • http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/social-and-personal-costs-of-arthritis-and-rheumatic-diseases_tn2008-583
  • READ
 
Chapter
 

Cost and Consumption of Medicines You do not have access to this content

English
Click to Access: 
    http://oecd.metastore.ingenta.com/content/3808801ec006.pdf
  • PDF
  • http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/social-and-personal-costs-of-arthritis-and-rheumatic-diseases/cost-and-consumption-of-medicines_9789289333146-6-en
  • READ
Author(s):
Nordic Council of Ministers

Hide / Show Abstract

Medical consumption is an important part of the arthritis and rheumatic patients’ life and the cost of that is carried by society (in the form of subsidies of costs) and by the patients themselves in the form of user charges. In this chapter we assess the extent of consumption and costs of medicines for our target groups.